Product Information for the User
Xeplion 25 mg Long-Acting Injectable Suspension
Xeplion 50 mg Long-Acting Injectable Suspension
Xeplion 75 mg Long-Acting Injectable Suspension
Xeplion 100 mg Long-Acting Injectable Suspension
Xeplion 150 mg Long-Acting Injectable Suspension
Paliperidone
Read this entire product information carefully before starting to use this medication, as it contains important information for you.
Xeplion contains the active ingredient paliperidone, which belongs to the class of antipsychotic medications and is used as a maintenance treatment for the symptoms of schizophrenia in adult patients who are stabilized with paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may initiate treatment with Xeplion without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are normally not present. For example, a person with schizophrenia may hear voices or see things that do not exist (known as hallucinations), have false beliefs (known as delusions) or have an abnormal distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimuli or may have difficulty speaking in a clear and logical manner. People who suffer from this disorder may also feel depressed, anxious, guilty, or tense.
Xeplion may help alleviate the symptoms of your illness and prevent them from recurring.
Do not use Xeplion
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to use Xeplion.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with similar medicines may have an increased risk of stroke or death (see section 4, possible side effects).
All medicines have side effects and some of the side effects of this medicine may worsen symptoms of other conditions. For this reason, it is important to discuss with your doctor any of the following diseases, which may worsen during treatment with this medicine:
If you have any of these diseases, please consult your doctor as it may be necessary to adjust your dose or keep you under observation for a time.
Because in very rare cases, a dangerously low number of a type of white blood cell necessary to fight infections in the blood has been observed in patients treated with this medicine, your doctor may check your white blood cell count.
Even if you have previously tolerated oral paliperidone or risperidone, rare allergic reactions may occur after receiving Xeplion injections. Seek immediate medical help if you experience a skin rash, swelling of the throat, itching or breathing problems, as these may be signs of a severe allergic reaction.
This medicine may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medicine, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medicine may mask the normal response of the body to the ingestion of toxic substances or other conditions, there is a possibility that it may mask the response.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not dilate as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery and this may cause eye damage. If you are planning to have eye surgery, be sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
Do not use this medicine in children under 18 years.
Use of Xeplion with other medicines
Inform your doctor if you are using, have used recently or may need to use any other medicine.
The use of this medicine with carbamazepine (an antiepileptic and mood stabilizer) may require a change in your dose of this medicine.
Since this medicine primarily acts on the brain, interaction with other medicines that also act on it may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medicines, opioids, antihistamines and sleep medicines.
Since this medicine may reduce blood pressure, you should be careful if you use this medicine with other medicines that also reduce blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless leg syndrome (e.g., levodopa).
This medicine may cause an anomaly in the electrocardiogram (ECG) that shows that a prolonged period is needed for an electrical impulse to travel through a certain part of the heart (known as "prolongation of the QT interval"). Other medicines that have this effect include some medicines used to treat heart rhythm or to treat infections, as well as other antipsychotics.
If you are prone to seizures, this medicine may increase your chances of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infections, as well as other antipsychotics.
Xeplion should be used with caution with medicines that increase the activity of the central nervous system (psychoestimulants such as methylphenidate).
Xeplion with alcohol
Alcohol should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medicine. Do not use this medicine during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last three months of pregnancy (last trimester of pregnancy): tremor, rigidity and/or muscle weakness, drowsiness, agitation, breathing problems and difficulty feeding. If your baby develops any of these symptoms, contact your doctor.
This medicine may pass from mother to baby through breast milk and may harm the baby. Therefore, do not breastfeed while using this medicine.
Driving and operating machinery
During treatment with this medicine, dizziness, extreme fatigue and vision problems (see section 4) may occur. This should be taken into account when requiring maximum attention, for example, when driving or operating machinery.
Xeplion contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
Your doctor or another healthcare professional will administer this medication. Your doctor will tell you when to receive the next injection. It is essential that you do not miss any scheduled doses. If you cannot attend your appointment with your doctor, make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medication in the upper arm approximately one week apart. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
If your doctor is switching you from long-acting risperidone injectable to this medication, you will receive the first injection of this medication (between 25 mg and 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
Your doctor may increase or decrease the amount of medication you receive at the time of the monthly scheduled injection based on your symptoms.
Patients with kidney problems
Your doctor may adjust the dose of this medication according to your renal function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medication if you have moderate or severe kidney problems.
Patients with advanced age
Your doctor may reduce the dose of this medication if your kidney function is decreased.
If you receive more Xeplion than you should
You will receive this medication under medical supervision, so it is unlikely that you will receive an excessive dose.
Patients who have received an excessive amount of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heart rate, low blood pressure, electrocardiogram abnormalities (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
If you stop treatment with Xeplion
If you stop receiving your injections, the effects of the medication will be lost. Do not stop using this medication unless your doctor tells you to, as your symptoms may return.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if:
The following side effects may occur:
Very common side effects: can affect more than 1 in 10 patients
Common side effects: can affect up to 1 in 10 patients
Uncommon side effects: can affect up to 1 in 100 patients
Rare side effects: can affect up to 1 in 10,000 patients
Unknown frequency: cannot be estimated from available data
Reporting of side effects
If you experience any side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational notification system included in theAppendix V.
By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
Composition of Xeplion
The active ingredient is paliperidone.
Each pre-filled syringe of Xeplion 25 mg contains 39 mg of palmitate of paliperidone.
Each pre-filled syringe of Xeplion 50 mg contains 78 mg of palmitate of paliperidone.
Each pre-filled syringe of Xeplion 75 mg contains 117 mg of palmitate of paliperidone.
Each pre-filled syringe of Xeplion 100 mg contains 156 mg of palmitate of paliperidone.
Each pre-filled syringe of Xeplion 150 mg contains 234 mg of palmitate of paliperidone.
The other components are:
Polisorbate 20
Polietilenglycol 4000
Citric acid monohydrate
Disodium phosphate anhydrous
Sodium diacetate monohydrate
Sodium hydroxide (for pH adjustment)
Water for injection
Appearance of the product and contents of the pack
Xeplion is a white to off-white prolonged-release injectable suspension, which comes in a pre-filled syringe.
Each pack contains 1 pre-filled syringe and 2 needles.
Start of treatment pack:
Each pack contains 1 pack of Xeplion 150 mg and 1 pack of Xeplion 100 mg.
Only some pack sizes may be marketed.
Marketing authorisation holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder.
België/Belgique/Belgien Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 | Lietuva UAB “JOHNSON & JOHNSON” Tel: +370 5 278 68 88 |
???????? ”??????? & ??????? ????????” ???? ???.:+359 2 489 94 00 | Luxembourg/Luxemburg Janssen-Cilag NV Tél/Tel: +32 14 64 94 11 |
Ceská republika Janssen-Cilag s.r.o. Tel:+420 227 012 227 | Magyarország Janssen-Cilag Kft. Tel.:+36 1 884 2858 |
Danmark Janssen-Cilag A/S Tlf: +45 45 94 82 82 | Malta AM MANGION LTD. Tel: +356 2397 6000 |
Deutschland Janssen-Cilag GmbH Tel: +49 2137-955-955 | Nederland Janssen-Cilag B.V. Tel: +31 76 711 1111 |
Eesti UAB “JOHNSON & JOHNSON” Eesti filiaal Tel.: +372 617 7410 | Norge Janssen-Cilag AS Tlf: +47 24 12 65 00 |
Ελλ?δα Janssen-Cilag Φαρμακευτικ? Α.Ε.Β.Ε Tηλ: +30 210 80 90 000 | Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
España Janssen-Cilag, S.A. Tel: +34 91 722 81 00 | Polska Janssen-Cilag Polska Sp. z o.o. Tel.: +48 22 237 60 00 |
France Janssen-Cilag Tel: 0 800 25 50 75 / +33 1 55 00 40 03 | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 |
Ísland Janssen-Cilag AB C/o Vistor hf Sími: +354 535 7000 | Slovenská republika Johnson & Johnson s.r.o. Tel: +421 232 408 400 |
Italia Janssen-Cilag SpA Tel: +39 02 2510 1 | Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 300 |
Κ?προς Βαρν?βας Χατζηπαναγ?ς Λτδ Tηλ: +357 22 207 700 | Sverige Janssen-Cilag AB Tel: +46 8 626 50 00 |
Latvija UAB “JOHNSON & JOHNSON” filiale Latvija Tel: +371 6789 3561 | United Kingdom Janssen-Cilag Ltd. Tel: +44 1 494 567 444 |
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu
This information is intended for healthcare professionals only and should be read in conjunction with the full prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use only. It should be visually inspected for any particulate matter before administration. Do not use the product if the syringe is not visually free of particulate matter.
The pack contains a pre-filled syringe and two safety needles (one 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle with a grey coloured shaft and one 23 gauge 1 inch [25.4 mm x 0.64 mm] needle with a blue coloured shaft) for intramuscular injection. Xeplion is also available in a Start of Treatment Kit containing two pre-filled syringes (150 mg + 100 mg) and two additional safety needles.
The first dose of Xeplion (150 mg) is administered on Day 1 in the deltoid muscle using the deltoid needle. The second dose of Xeplion (100 mg) is administered also in the deltoid muscle one week later (Day 8) using the deltoid needle.
If the patient is switched from risperidone prolonged-release injectable to Xeplion, the first Xeplion injection (dose range 25 mg to 150 mg) can be administered in the deltoid muscle or gluteus muscle, using the appropriate needle for the injection site, at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in either the deltoid muscle or gluteus muscle using the appropriate needle for the injection site.
For deltoid muscle injection, if the patient weighs <90>23kg, use the 23 gauge 1 inch [25.4 mm x 0.64 mm] needle (needle with blue shaft); if the patient weighs?90 kg, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with grey shaft).
For gluteus muscle injection, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with grey shaft).
8a
8b
Unused medicinal product and all materials that have come into contact with it will be disposed of in accordance with local regulations.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.